arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ClearPoint Neuro, Inc.

CLPT
$14.23 ▲ +0.85 (+6.31%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

ClearPoint Neuro, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $402.9M
Dividend Yield
Revenue Growth 17.8%
Op. Margin -65.4%
ROIC -31.4%
FCF / Share $-0.86
Trailing P/E
Price / Book 14.9x
FCF Yield
Debt / Equity 1.75
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$36.97M
↑ +17.8%
Net Income Profit after all expenses
$-25.54M
↓ -35.0%
Operating Margin Operating profit as % of sales
-65.4%
↓ -4.0% 4th
FCF / Share Free cash flow per share
$-0.86
↓ -153.0%
Long-Term Debt Long-term obligations
$49.08M
↑ +393.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
10
Financial Health
18
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 64 quarters